BioSpace News Archive

Oryzon Genomics, S.A. today announced that it will present final data from its Phase IIb PORTICO trial, which investigated the efficacy of vafidemstat in the treatment of Borderline Personality Disorder (BPD), as an oral presentation at the 37th European College of Neuropsychopharmacology (ECNP) annual conference, to be held on September 21-23, 2024 in Milan, Italy.

Surgence™, a cloud-based digital platform created by Concordance Innovations, a wholly owned subsidiary of Concordance Healthcare Solutions, is pleased to announce a collaboration with Mayo Clinic to integrate Surgence into their digital supply chain, enhancing the Surgence platform.

Solarea Bio, a pioneering biotechnology company focused on developing solutions to improve human health by harnessing the edible plant microbiome, announces the appointment of Ilissa Larimore as Chief Commercial Officer.

BrainStorm Cell Therapeutics Inc. ment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm’s Phase 3b clinical trial for NurOwn.

Concerto Biosciences, a Cambridge-based biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1, first-in-human trial of Ensemble No.2 (ENS-002), an investigational live biotherapeutic product (LBP) to treat atopic dermatitis (AD).

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Prochlorperazine Edisylate Injection, USP in the United States as a therapeutic generic equivalent for COMPAZINE® as approved by the U.S. Food and Drug Administration.

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia.

Scale Biosciences announced the availability of ScalePlex an advanced single cell multiplexing technology designed to simplify large-scale single cell genomics studies.

Ricoh USA, Inc. and Stratasys Ltd. (NASDAQ: SSYS) today announced the enrollment of the first patient in a groundbreaking clinical study aimed to evaluate the use of 3D printed models for orthopedic oncology.

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors.